SBIR Phase I Topic 410 - Cancer Clinical Trials Recruitment and Retention Tools for Participant Engagement.

SBIR 第一阶段主题 410 - 用于参与者参与的癌症临床试验招募和保留工具。

• 批准号: 10265761
• 负责人: Selin Kurnaz
• 金额: $ 39.96万
• 依托单位: MASSIVE BIO, INC.
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-16 至 2021-06-15
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10265761
• 关键词: Access to Information; Address; Adoption; Awareness; Clinical Research; Clinical Trials; Communities; Computerized Medical Record; Contracts; Evaluation; Funding; NCI-Designated Cancer Center; Participant; Patients; Phase; Price; Protocols documentation; Provider; Small Business Innovation Research Grant; Specific qualifier value; System; Testing; base; cancer clinical trial; deep learning; design; human subject protection; improved; oncology trial; peer coaching; prototype; recruit; screening; success; support tools; tool; usability

The proposed contract is designed to refine and test the feasibility and usability of a Deep Learning Clinical Trial Matching System (DLCTMS) for improving accrual across multiple oncology trials at an NCI-designated Cancer Center (NCICC). This project explicitly meets NCI-identified needs for clinical trial support tools that a) identify protocol barriers to recruitment and present options for addressing the challenge, b) identify effective recruitment strategies, c) integrate with electronic medical records, d) allow for tracking screening efforts, d) are easily adaptable for different trials, e) include provider-based tools to facilitate discussion with potential participants, f) provide access to peer mentors and patient navigators, and g) increase awareness and provide easy access to information on all ongoing clinical trials.

拟议的合同旨在完善和测试一个深度的可行性和可用性 学习临床试验匹配系统（DLCTMS），用于提高多个 在NCI-designated Cancer Center（NCICC）进行的肿瘤学试验。该项目明确满足 NCI确定的临床试验支持工具需求，a）确定方案障碍， 招募并提出应对挑战的备选方案，B）确定有效的 招聘战略，c）与电子病历相结合，d）允许跟踪 筛选工作，d）易于适应不同的试验，e）包括基于提供者的工具 促进与潜在参与者的讨论，f）提供与同行导师的接触机会， 患者导航器，以及g）提高意识并提供对以下信息的轻松访问 所有正在进行的临床试验